The company is the latest facing historic losses as pharmaceutical firms compete to develop a weight-loss pill.

Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...

Viking Therapeutics (VKTX) stock drops as its oral obesity drug VK2735 trails Novo's (NVO) oral Wegovy and Lilly's (LLY) ...

Eli Lilly's rare 40-year bond sparks talk of a Viking Therapeutics (VKTX) acquisition. Experts say LLY is "setting up for ...

Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral ...

When bad news drops, investors have a tendency to sell first and ask questions later. Let's take a closer look at why Viking ...

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra ...

VK2735 met its primary endpoint but failed to outdo competitors Novo Nordisk and Eli Lilly in terms of body weight loss.

Viking Therapeutics reported positive Phase 2 results for VK2735, showing significant weight loss and safety in obesity ...

Eli Lilly (NYSE: LLY) has become a giant in what may be a $100 billion market a few years from now. I'm talking about the world of weight loss drugs.

Viking Therapeutics' dual-formulation obesity program could capture the most profitable patient segment starting in 2027. At 29 times forward earnings, Lilly stock assumes flawless execution with no ...